课题基金 / 基金详情

High Throughput Assays to Identify Inhibitors of SUMO-mediated Protein-Protein In

High Throughput Assays to Identify Inhibitors of SUMO-mediated Protein-Protein In
高通量测定法鉴定 SUMO 介导的蛋白质-蛋白质抑制剂
批准号:
8413730
负责人:
Yuan Chen
金额:
$4.15万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-05 至 2014-01-31

项目摘要

项目成果

Yuan Chen的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): One of the biggest challenges in biomedical research is to design ligands for novel molecular targets so as to better understand the molecular mechanisms of life-threatening diseases and develop innovative, more effective treatments. Regrettably, progress along this line has been slow / among the approximately 50 new drugs approved by the Food and Drug Administration each year, only 3 - 5 address a new molecular target. SUMO (Small Ubiquitin-like Modifier) is one of the newly identified targets with importance in treating cancer and viral infection, for which inhibitors have not been developed to date. Protein modifications by the SUMO family of proteins regulate essential functions such as gene transcription, cell cycle progression and DNA repair. Our preliminary data has shown that inhibition of SUMO-mediated protein-protein interactions can inhibit DNA repair and sensitize cancer cells to chemotherapy and radiation. The overall goal of the proposal is to develop high throughput screening (HTS) assays to identify inhibitors for SUMO-dependent protein-protein interactions. Inhibitors of the homologous ubiquitin-proteosome pathway have been critical in studies of ubiquitin- dependent degradation and have also been extremely successful as anti-cancer therapeutics. Inhibitors of SUMO-dependent protein-protein interactions hold similar promise and could lead to the establishment of a new paradigm in the treatment of human diseases. We propose to develop HTS assays using the AlphaScreen technology, fluorescence resonance energy transfer and cell- based high content imaging approaches to identify such inhibitors. These assays will be used in automated high throughput screening (HTS) by the Molecular Libraries Production Centers Network (MLPCN). We will also perform studies using cellular and animal models to determine the research and therapeutic potentials of the lead inhibitors identified from HTS. PUBLIC HEALTH RELEVANCE: The overall goal of this proposal is to develop high throughput screening assays (HTS) to identify inhibitors for SUMO-mediated protein-protein interactions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Surgical Oncologists as Scientists (SOAS) Training Program
SUMO Modification and Cancer Therapy
SUMO Modification and Cancer Therapy
K-Ras sumoylation in cell proliferation and transformation